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Introduction: Vital drugs may be degraded or sequestered in extracorporeal membrane oxygenation (ECMO)
circuits, with lipophilic drugs considered to be particularly vulnerable. However, the circuit effects on protein-bound
drugs have not been fully elucidated. The aim of this experimental study was to investigate the influence of plasma
protein binding on drug disposition in ex vivo ECMO circuits.
Methods: Four identical ECMO circuits comprising centrifugal pumps and polymethylpentene oxygenators and
were used. The circuits were primed with crystalloid, albumin and fresh human whole blood and maintained
at a physiological pH and temperature for 24 hours. After baseline sampling, known quantities of study drugs
(ceftriaxone, ciprofloxacin, linezolid, fluconazole, caspofungin and thiopentone) were injected into the circuit to
achieve therapeutic concentrations. Equivalent doses of these drugs were also injected into four polypropylene jars
containing fresh human whole blood for drug stability testing. Serial blood samples were collected from the
controls and the ECMO circuits over 24 hours, and the concentrations of the study drugs were quantified using
validated chromatographic assays. A regression model was constructed to examine the relationship between circuit
drug recovery as the dependent variable and protein binding and partition coefficient (a measure of lipophilicity) as
explanatory variables.
Results: Four hundred eighty samples were analysed. There was no significant loss of any study drugs in the controls
over 24 hours. The average drug recoveries from the ECMO circuits at 24 hours were as follows: ciprofloxacin 96%,
linezolid 91%, fluconazole 91%, ceftriaxone 80%, caspofungin 56% and thiopentone 12%. There was a significant
reduction of ceftriaxone (P = 0.01), caspofungin (P = 0.01) and thiopentone (P = 0.008) concentrations in the ECMO
circuit at 24 hours. Both protein binding and partition coefficient were highly significant, with the model possessing a
high coefficient of determination (R2 = 0.88, P <0.001).
Conclusions: Recovery of the highly protein-bound drugs ceftriaxone, caspofungin and thiopentone was significantly
lower in the ECMO circuits at 24 hours. For drugs with similar lipophilicity, the extent of protein binding may determine
circuit drug loss. Future clinical population pharmacokinetic studies should initially be focused on drugs with greater
lipophilicity and protein binding, and therapeutic drug monitoring should be strongly considered with the use of
such drugs.* Correspondence: Kiran.shekar@health.qld.gov.au
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Extracorporeal membrane oxygenation (ECMO) is es-
tablishing itself as a viable ultimate support therapy for pa-
tients with severe cardiorespiratory failure resulting from a
variety of clinical conditions, and its scope continues to
expand [1-3]. Patients on ECMO receive multiple drugs in
an attempt to either reverse the underlying pathology or
to minimise and/or treat complications. In venovenous
ECMO, a high proportion of the native cardiac output is
required to pass through the oxygenator to achieve ad-
equate systemic oxygenation. In venoarterial ECMO, the
ECMO circuit flows may exceed native cardiac output [4].
This transit of blood through the extracorporeal circuit
may result in degradation and/or sequestration of circulat-
ing compounds, including administered drugs [5].
In addition, ECMO is associated with significant phar-
macokinetic (PK) alterations [6], most important of which
is an increased volume of distribution (VD) and decreased
drug clearance (CL). From a PK point of view, the addition
of an extracorporeal circuit that can sequester and/or de-
grade drugs during transit, as well as modulate their VD
and CL, which presents a significant challenge. The drug,
device and disease factors affecting PK during ECMO are
very difficult to characterise in a critically unwell patient,
and, as such, laboratory-based research that mimics the
clinical scenario [7] should be used to fully understand the
complex mechanisms behind the PK alterations.
Drug factors such as protein binding and lipophilicity
play a key role in their absorption, distribution, metabolism
and excretion. Drugs are transported partly as unbound
drug and partly reversibly bound to blood components
such as plasma proteins and blood cells. The unbound
drug then diffuses to extravascular or tissue sites, where
the pharmacologic effects are observed. The dynamic rela-
tionship between unbound drug concentrations in the
blood and tissue sites determines the overall efficacy of
the drug. The distribution of the drug and its tissue pene-
tration are determined mainly by the extent of protein
binding, degree of ionization, and lipophilicity [8]. Lipo-
philicity is the main determinant of a drug’s permeability.
It is traditionally assessed by measuring the drug distribu-
tion between immiscible phases of n-octanol and water.
The ratio of a drug’s concentration in n-octanol and water
is referred to as the partition coefficient (P), the logarithm
of which (log P) is commonly used to describe the lipophi-
licity of therapeutic drugs [9].
ECMO circuits, by binding both circulating proteins
and the drugs, can therefore significantly influence the
PK of administered drugs in critically ill patients. How-
ever, most available data on disposition of drugs in ECMO
circuits are derived from neonatal studies that have used
older generation of ECMO circuits [6]. Data from these
studies reveal significant sequestration of drugs in the
ECMO circuit [6,10], with the extent of loss dependentupon their physicochemical properties, type and age of
the circuit and the pumps used [11,12]. There are limited
data from studies based on circuits used in adult patients.
Even though lipophilicity of drugs is widely believed to be
a major drug-related factor for circuit sequestration [5,11],
the implication of protein binding on circuit disposition
has not been fully elucidated.
To address this, we undertook drug disposition studies
in contemporary ECMO circuitry in adult patients using
an ex vivo model of ECMO. We hypothesised that lipo-
philic and protein-bound drugs are more prone to seques-
tration in ECMO circuits. We have previously reported
results for five drugs (meropenem, vancomycin, fentanyl,
midazolam and morphine [5]), which highlighted the role
of drug stability and lipophilicity in determining circuit
drug loss. In this article, we present results for another six
study drugs (ceftriaxone, ciprofloxacin, linezolid, flucona-
zole, caspofungin and thiopentone) and describe the influ-
ence of protein binding on drug disposition in ECMO
circuits.
Materials and methods
Ethical approval was obtained from the Research, Ethics
and Governance Unit, The Prince Charles Hospital, Metro
North Hospital & Health Service, Brisbane, Australia
(HREC/12/QPCH/90). Informed consent was not rele-
vant, as no human subjects were enrolled in this study.
The methods have been published previously [5,13], and
therefore only a brief overview of the methods is pre-
sented here.
Extracorporeal membrane oxygenation circuits
Four pulse life support (PLS) ECMO circuits were used.
They consisted of Bioline tubing (Netafim, Fresno, CA,
USA), a QUADROX D oxygenator and RotaFlow pump
head (MAQUET Cardiopulmonary, Hirrlingen, Germany).
A bladder reservoir (R-38; Medtronic, Minneapolis, MN,
USA) was added to provide compliance to the circuit and
allow multiple fluid sampling from the closed circuit. The
circuits were primed with Plasma-Lyte P-148 (Baxter
Healthcare, Toongabbie, Australia) and then exchanged
with ALBUMEX 4 (human albumin 40 g/L; CSL, Parkville,
Australia) and fresh human whole blood (less than 5 days
old, mean volume 420 ± 52 ml, provided by the Australian
Red Cross Blood Service). Porcine mucous heparin (Pfizer
Australia, West Ryde, Australia) was added to the circuits
(5,000 U).
The final volume of the pressurised circuit was 668 ±
1.7 ml. Activated clotting time was maintained between
220 and 250 seconds. The circuit flow rate, oxygen ten-
sion and temperature were kept between 4 and 5 L/min,
between 150 and 200 mmHg and at 37°C, respectively,
to maintain the pH of the circulating blood in the range
of 7.20 to 7.55 by addition of carbon dioxide gas to the
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morphine (100 μg), midazolam (100 μg), meropenem (10 mg),
vancomycin (40 mg), propofol (1 mg), dexmedetomidine
(5 μg), thiopentone (20 mg), ceftriaxone (50 mg), linezolid
(10 mg), ciprofloxacin (5 mg), fluconazole (10 mg) and
caspofungin (5 mg) were injected postoxygenator as a
single bolus. The drugs with known incompatibilities
to study drugs (for example, gentamicin and ticarcillin/
clavulanate) were excluded. These bolus doses were se-
lected to produce concentrations similar to clinical con-
centrations. Larger doses were used for the drugs that
exhibit high protein binding.
Controls
Four polypropylene jars with tight caps were filled with
50 ml of fresh human whole blood, and 500 U of unfrac-
tionated heparin were added to the jars for anticoagula-
tion. Fentanyl (1.5 μg), morphine (7.5 μg), midazolam
(7.5 μg), meropenem (0.75 mg), vancomycin (3 mg), pro-
pofol (75 μg), dexmedetomidine (0.375 μg), thiopentone
(1.5 mg), ceftriaxone (3.75 mg), linezolid (0.75 mg), cip-
rofloxacin (0.375 mg), fluconazole (0.75 mg) and caspo-
fungin (0.375 mg) were added to the control jars after
collection of baseline blood samples. These quantities
were chosen to produce study drug concentrations simi-
lar to those achieved in the ECMO circuit. The jars were
then placed in an incubator at 37°C and rocked continu-
ously to ensure even distribution of the drugs.
Blood sample collection
Postoxygenator blood was collected into lithium heparin
tubes (5 ml) at baseline and at 2, 5, 15 and 30 minutes
and 1, 2, 6, 12 and 24 hours after addition of the drugs
to the circuit. Blood samples (5 ml) were also obtained
from the control jars at time intervals identical to those
of the circuit. All blood samples were stored on ice prior
to centrifugation (10 minutes at 3,000 g), and the plasma
was separated and stored in clean, prelabelled polypro-
pylene cryogenic vials at −80°C until analysis.
Measurement of drugs in plasma samples
A robotic online solid-phase extraction (SPE) Symbiosis
Pharma system (Spark Holland, Emmen, The Netherlands)
was used to extract the thiopental and thiopental-d5
(internal standard) from plasma samples. The SPE was con-
ducted using a HySphere C18 cartridge (Spark Holland),
and the analytes eluted from the cartridges were directly
transferred to an XTerra MS C18 column (Waters,
Milford, MA, USA). Mass spectrometry (MS) in electro-
spray ionization in negative mode (QTRAP 5500; AB SCIEX,
Concord, ON, Canada) was used as the detector. The liquid
chromatography and extraction methods used were created
by Symbiosis Pro for Analyst (version 2.1.0.0; Spark Holland)
and submitted to the MS controlling software (Analyst 1.6).For antibiotic analysis, plasma sample aliquots (100 μl)
were combined with an internal standard before protein
precipitation by addition of trichloroacetic acid (ciprofloxa-
cin) or acetonitrile (ceftriaxone, caspofungin, linezolid and
fluconazole). Ceftriaxone supernatant was washed with
dichloromethane prior to instrumental analysis. Ceftri-
axone and ciprofloxacin were analysed on a Prominence
high-performance liquid chromatography system (Shimadzu,
Kyoto, Japan). Caspofungin, Linezolid and Fluconazole were
analysed on a Nexera-8030+ ultra-high-performance liquid
chromatography tandem MS (Shimadzu, Kyoto, Japan).
All separations were performed by reverse-phase chroma-
tography. Ciprofloxacin was detected by fluorescence,
ceftriaxone by ultraviolet detection, and caspofungin,
linezolid and fluconazole by triple-quadrupole MS. All
assays were validated and conducted according to the
US Food and Drug Administration guidance on bioa-
nalysis [14].
Statistical analysis
The data consisted of a longitudinal and correlated time
series. For each drug in both the control and experimen-
tal (circuit) assays, the drug assayers were assumed to be
independent of one another. For continuous data, normal-
ity was checked using a Shapiro-Wilk test. Non-normally
distributed data were transformed. The data were analysed
using a time series in a generalized linear model with a
normal link function. The results are reported as the
mean ± standard deviation (SD) for normally distributed
data, median (interquartile range) for non-normal or cat-
egorical data and the proportion—either fractional or as a
percentage—for binary data. For the purposes of analysis,
all drug levels were referenced to the concentration of that
drug at zero hours (baseline) and are reported as the per-
centage change from that baseline.
An ordinary (least-squares) regression model was con-
structed to examine the relationship between the two
explanatory variables, protein-bound fraction (FB) and
log partition coefficient (log P) and the outcome vari-
able, fraction of drug remaining at 24 hours (FC24).
Model coefficients and their 95% confidence intervals
are reported. The final model was also tested for fit to
the data (adjusted R2), and its residuals were examined
for normality and homoscedasticity. Throughout, the
level of significance was set at P <0.05. STATA™ software
(version 12.0; StataCorp, College Station, TX, USA) was
used for all analyses.
Results
The ex vivo circuits were maintained under physiological
conditions for 24 hours without complications. The
mean (SD) total protein and albumin concentrations in
the circuits were 33 (2.5) g/L and 25 (0.9) g/L, respect-
ively. The measured mean (SD) pH in the individual
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(0.15), 7.39 (0.3) and 7.26 (0.14). A total of 480 samples
(80 per drug) were analysed. The changes in drug con-
centrations relative to the baseline over time are sum-
marised in Figure 1. Testing confirmed that all baseline
plasma samples (prior to study drug injection into the
circuit) were free of study drugs. There were no statisti-
cally significant differences in individual study drug re-
coveries between the four circuits or controls. The mean
drug recoveries from the circuits and the control jars at
24 hours relative to baseline were, respectively, 80% and
102% for ceftriaxone, 96% and 119% for ciprofloxacin,
91% and 102% for linezolid, 91% and 102% for flucona-
zole, 56% and 99% for caspofungin, and 12% and 102% for
thiopentone. The reduction in ceftriaxone (P = 0.01), cas-
pofungin (P = 0.01) and thiopentone (P = 0.008) concen-
trations in the ECMO circuit at 24 hours were all
significant. Although there was some variability in pH be-
tween circuits, there was no significant independent effect
of pH on individual drug disposition in the circuits.Figure 1 Percentages of drug remaining in ex vivo extracorporeal me
time. For clarity, 95% confidence intervals are shown only for the experime
identified by the continuous lines and open symbols. The circuit group is iDrug physicochemical data were obtained from the
DrugBank online database [15] and then correlated with
circuit drug behaviour. The relationships of study drug
lipophilicity and protein binding with circuit drug con-
centrations are summarised in Table 1 and Figure 2. A
linear regression model was constructed to examine the
association between log P and the FB in the prediction
of FC24. In this model, both predictors were highly sig-
nificant, with model diagnostics revealing normally
distributed, homoscedastic residuals. The following model
equation was used:
FC24 ¼ 1:21 − 0:17 log P − 0:69 FB R2 ¼ 0:88ð Þ:
The confidence intervals and associated P-values for the
coefficients were as follows:
Log P −0:17; −0:13½ ; P < 0:001
FB −0:86; −0:52½ ;P < 0:001mbrane oxygenation circuits and the controls plotted against
ntal (circuit) group at times 6, 12 and 24 hours. The control group is
dentified by the dashed lines and solid symbols.
Table 1 Drug recoveries in ex vivo circuits and controls relative to baseline and their relationship to lipophilicity and
protein-binding characteristicsa
Drug Mean (SD) drug recovery (%)
from controls at 24 hr
Mean (SD) drug recovery (%)
from circuits at 24 hr
Lipophilicity (log P) Protein binding (%)
Ciprofloxacin 119 (4) 96 (17) 2.3 20 to 40
Fluconazole 102 (1) 91 (4) 0.4 12
Linezolid 102 (4) 91 (4) 0.9 31
Ceftriaxone 102 (1) 80 (6) −1.7 95
Caspofungin 99 (8) 56 (13) 0.1 97
Thiopentone 102 (8) 12 (5) 2.3 80
Fentanyl* 82 (6.3) 3 (3.8) 3.9 85
Midazolam* 100 (3.6) 13 (2) 3.9 92
Meropenem* 42 (1.5) 20 (7) −0.6 2
Vancomycin* 98 (9) 91 (11) −3.1 55
Morphine* 103 (11) 97 (2.6) 0.8 30
aLog P, Log; SD, Standard deviation. Drugs that are significantly lost in the extracorporeal membrane oxygenation circuit are highlighted. Asterisks indicate
previously published data from the same experiment [5].
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This systematic investigation provides useful insights
into the drug factors that influence drug disposition in
circuitry currently used in adult patients undergoing
ECMO. Based on a representative group of study drugs
with diverse lipophilicity and protein-binding character-
istics, this study demonstrates the importance of drug
factors altering PK during ECMO. More important, the
results indicate that for a given degree of lipophilicity,
the extent of protein binding may determine circuit drug
disposition. This is highly relevant, as the PK of highly
protein-bound drugs are significantly affected during
critical illness [16,17], and therapeutic drug monitoring
(TDM) for many of these drugs is not routinely available
at the current time.
The findings also highlight that there is considerable
between-drug variability in the degree of drug sequestra-
tion. Drugs with significantly reduced concentrations at
24 hours were either highly protein-bound (>80%), highly
lipophilic (log P >2.3) or both. As previously reported [5],
meropenem (protein binding: 2%, log P: −0.6) was the
only drug that did not conform to this trend, and its cir-
cuit loss can be attributed to its instability at physiological
temperature [5,18]. Most other drugs that do not exhibit
extremes of protein binding or lipophilicity remained
relatively stable in the ex vivo ECMO circuit. Thus,
drug stability at room temperature and at 37°C is also
an important consideration for drugs prescribed dur-
ing ECMO.
For a given solubility characteristic, the degree of pro-
tein binding appeared to be the main determinant of circuit
drug concentration. For example, although ciprofloxacin
and thiopentone have similar lipophilicity (log P: 2.3),
greater reductions in 24-hour plasma concentrations were
observed for thiopentone (88%), the more protein-bounddrug as compared with ciprofloxacin (4%). For the hydro-
philic drugs vancomycin and ceftriaxone (log P: −3.1
and −1.7, respectively), protein binding (55 and 83%
to 95%, respectively) once again appeared to be the key
determinant of circuit drug recovery (91% and 80%, re-
spectively) at 24 hours.
The mean (±SD) total protein and albumin concentra-
tions (33 ± 2.5 g/L and 25 ± 0.9 g/L, respectively) in the
ex vivo circuit were quite similar to what is encountered
in critically unwell patients [19]. As unbound study drug
concentrations were not measured, it remains unclear
whether protein-bound or -unbound fractions are more
susceptible to circuit degradation and/or sequestration.
In one study, there was a more significant loss of ampicil-
lin (a relatively hydrophilic and less protein-bound drug)
in neonatal ex vivo crystalloid-primed circuits [20] than in
blood-primed circuits (72% vs. 15% lost at 24 hours). This
indicates that the ECMO circuits can bind both pro-
teins and drugs, and it is unclear if there is any competi-
tive binding between them and, if so, whether such a
phenomenon is concentration-dependent. Thus, the net
circuit loss of a drug may represent a balance between
binding to circuit components versus extent of protein
binding. In addition, similar to their critically ill counter-
parts [16], patients receiving ECMO have physiological al-
terations that may influence protein binding, and a
resulting increase in unbound drug fraction may enhance
circuit losses [6]. This may, in part, explain the high VD re-
ported for drugs in patients receiving ECMO.
It is unclear if protein binding and lipophilicity have
an additive effect on circuit drug sequestration, as some
of the greatest decrements in circuit drug concentrations
(>80%) reported at 24 hours [5] relate to drugs that have
high degrees of both lipophilicity and protein binding
(fentanyl, midazolam and thiopentone). This may be further
Figure 2 Recovery of drugs in percent from extracorporeal membrane oxygenation circuit at 24 hours. (a) Lipophilicity expressed as log
partition coefficient (log P) values. (b) Protein binding expressed as percentage. For each drug, the mean concentration is indicated by a crossbar
and the upper and lower 95% confidence intervals are indicated by crosses. FCZ, Fluconazole; LEL, Linezolid; CRF, Ciprofloxacin; STP, Sodium
thiopentone; CTX, Ceftriaxone; CPF, Caspofungin.
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ciprofloxacin (despite having a lipophilicity similar to that
of thiopental) remained relatively stable in the circuit. The
mechanisms that independently lead to circuit sequestra-
tion of a highly protein-bound drug are currently unclear.
In a study using ex vivo neonatal circuits [21], up to 80%
of the lipophilic and highly protein-bound drug fentanyl
was lost in ECMO circuits without oxygenators at 6 hours,
and addition of an oxygenator to the circuit only increased
the losses by another 6%. It is possible that circuit sitesthat bind albumin and other circulating proteins upon
priming or after passage of patients’ own blood may in
turn bind to the administered drugs that exhibit high pro-
tein binding. Studies in which researchers have compared
drug losses in clinically used versus new neonatal circuits
have demonstrated significant variability in drug sequestra-
tion between the used and new circuits [11,12,22]. Conse-
quently, it is still unclear if saturation of the drug-binding
sites in the ECMO circuit over time occurs. Given that
ECMO therapy may continue for many weeks, the time
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sites in the ECMO circuit also remains a subject for future
studies. This could potentially be investigated with repeat
dose experiments in a similar ex vivo model.
Studies in neonatal ECMO circuits have also demon-
strated variable sequestration of drugs based on the dif-
ferent circuits, oxygenators and pumps used [11]. Even
though these studies clearly identify lipophilicity as a
factor for circuit drug sequestration, there are no pub-
lished experiments that explore the impact of protein
binding to the extent described in this study. Wildschut
et al. [11] reported an 84% recovery for hydrophilic drug
cefazolin (protein binding of 84%) at 3 hours in circuits
with centrifugal pumps and polypropylene hollow fibre
oxygenators. With silicone membrane oxygenators, the
drug recoveries observed in blood-primed circuits by
Mehta et al. for ampicillin, cefazolin and voriconazole
were 85%, 79% and 29%, respectively. Although these
three drugs exhibit contrasting degrees of lipophilicity
(log P: −2, −1.5 and 1.0, respectively) and protein bind-
ing (25%, 84% and 58%, respectively), it should be noted
that the least protein-bound and lipophilic drug of the
three drugs—ampicillin—had the best recovery profile at
24 hours, despite its instability issues.
This ex vivo study has some limitations. The concur-
rent presence of several other physically compatible
study drugs in the circuit and control jars mimicked the
clinical scenario where patients receive these drugs con-
currently, but it may have had an impact on competitive
binding to blood proteins or the circuit components. Al-
though there was some variability in pH between cir-
cuits, there was no significant independent effect of
change in pH on individual drug disposition in the cir-
cuits, and similar drug loss trends were observed in all
circuits. A reservoir bladder was necessary to allow re-
moval of multiple blood samples from the otherwise
non-compliant circuit, which may have influenced the
circuit drug loss. Similarly, quantification of drug lost in
control jars due to binding of drugs to the polypropylene
container was not feasible, although this is suspected of
being negligible because the surface area of the control
experiment was significantly less.
The findings of this study may have significant impli-
cations for both the choice and the dosing of an indi-
vidual drug prescribed during ECMO. Although any
drug can be affected, these findings will inform the
design of future clinical PK studies [23] that are the
next logical step in the evaluation of the impact of
the circuit and drug factors on PK in critically unwell
patients receiving ECMO and in the development of
robust dosing guidelines. Given that most of these drugs
are highly relevant for this patient population, TDM,
where available, is also strongly recommended, pend-
ing clinical PK data.Conclusions
This ex vivo study highlights the role of the ECMO cir-
cuit and drug factors in altering PK during ECMO. In
addition to previously identified drug factors such as in-
stability and lipophilicity, this study highlights the influ-
ence of protein biding on drug disposition in ECMO
circuits. The drugs that are most significantly affected need
expedited evaluation in clinical population PK studies and
in further mechanistic studies in animal models so that
the in vivo impact of such circuit drug losses are fully elu-
cidated. Such mechanistic and clinical PK data can then
assist the development of meaningful dosing simulations
and robust dosing guidelines for the prescription of anti-
biotic and sedative drugs given during ECMO.
Key messages
 Drug stability, lipophilicity and protein binding are
the three key drug factors that influence drug
disposition in ECMO circuits.
 Protein-bound drugs appear to be more significantly
sequestered in ex vivo ECMO circuits.
 When multiple drugs with similar degrees of protein
binding are administered, circuit drug loss is
determined by degree of lipophilicity and vice versa.
 Sequestration of drugs in the circuit may have
implications on both the choice and dosing of a
particular drug prescribed during ECMO.Abbreviations
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